See how Parexel are bringing together regulatory and market access experts to help companies developing rar...
Other content in this Stream
See how Parexel are bringing together regulatory and market access experts to help companies developing rare and orphan disease products. Learn more about our Regulatory & Access Consulting Group: htt
In February 2019, National Drug Regulators in China approved the country’s first ever biosimilar product referencing Rituxan, a monoclonal antibody. This biosimilar product, HLX01...
In this on-demand webinar, Parexel experts discuss the growing interest in RWE from both regulators and payors and the advantages of using real-world data (RWD) to streamline the research process.
Early engagement with regulatory authorities can help boost regulatory success rates and also help shorten clinical development timelines.
Read why 18 of the top 20 pharmaceutical companies are using a module of the Liquent InSight® platform as their single, authoritative source for regulatory information.
This article examines reasons for the high failure rate of Phase III studies and innovative approaches companies can take to mitigate risk.
Create a strong RWE evidence strategy that addresses three critical factors: product differentiation, clinical outcomes in the real world and evidence gaps that may crop up suddenly.